A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine
Identifieur interne : 000747 ( Pmc/Curation ); précédent : 000746; suivant : 000748A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine
Auteurs : Alex B. Ryder [États-Unis] ; Linda Buonocore [États-Unis] ; Leatrice Vogel [États-Unis] ; Raffael Nachbagauer [États-Unis, Autriche] ; Florian Krammer [États-Unis] ; John K. Rose [États-Unis]Source :
- Journal of Virology [ 0022-538X ] ; 2014.
Abstract
The emergence of novel influenza viruses that cause devastating human disease is an ongoing threat and serves as an impetus for the continued development of novel approaches to influenza vaccines. Influenza vaccine development has traditionally focused on producing humoral and/or cell-mediated immunity, often against the viral surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). Here, we describe a new vaccine candidate that utilizes a replication-defective vesicular stomatitis virus (VSV) vector backbone that lacks the native G surface glycoprotein gene (VSVΔG). The expression of the H5 HA of an H5N1 highly pathogenic avian influenza virus (HPAIV), A/Vietnam/1203/04 (VN1203), and the NA of the mouse-adapted H1N1 influenza virus A/Puerto Rico/8/34 (PR8) in the VSVΔG vector restored the ability of the recombinant virus to replicate in cell culture, without the requirement for the addition of trypsin. We show here that this recombinant virus vaccine candidate was nonpathogenic in mice when given by either the intramuscular or intranasal route of immunization and that the
Url:
DOI: 10.1128/JVI.03246-14
PubMed: 25540378
PubMed Central: 4325733
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000747
Links to Exploration step
PMC:4325733Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine</title>
<author><name sortKey="Ryder, Alex B" sort="Ryder, Alex B" uniqKey="Ryder A" first="Alex B." last="Ryder">Alex B. Ryder</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Yale University School of Medicine, New Haven, Connecticut</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff2">Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Buonocore, Linda" sort="Buonocore, Linda" uniqKey="Buonocore L" first="Linda" last="Buonocore">Linda Buonocore</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Yale University School of Medicine, New Haven, Connecticut</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name>
<affiliation wicri:level="1"><nlm:aff id="aff3">Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nachbagauer, Raffael" sort="Nachbagauer, Raffael" uniqKey="Nachbagauer R" first="Raffael" last="Nachbagauer">Raffael Nachbagauer</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff5">Faculty of Life Sciences, University of Vienna, Vienna, Austria</nlm:aff>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Faculty of Life Sciences, University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Krammer, Florian" sort="Krammer, Florian" uniqKey="Krammer F" first="Florian" last="Krammer">Florian Krammer</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rose, John K" sort="Rose, John K" uniqKey="Rose J" first="John K." last="Rose">John K. Rose</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Yale University School of Medicine, New Haven, Connecticut</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25540378</idno>
<idno type="pmc">4325733</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325733</idno>
<idno type="RBID">PMC:4325733</idno>
<idno type="doi">10.1128/JVI.03246-14</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000747</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000747</idno>
<idno type="wicri:Area/Pmc/Curation">000747</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000747</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine</title>
<author><name sortKey="Ryder, Alex B" sort="Ryder, Alex B" uniqKey="Ryder A" first="Alex B." last="Ryder">Alex B. Ryder</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Yale University School of Medicine, New Haven, Connecticut</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff2">Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Buonocore, Linda" sort="Buonocore, Linda" uniqKey="Buonocore L" first="Linda" last="Buonocore">Linda Buonocore</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Yale University School of Medicine, New Haven, Connecticut</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name>
<affiliation wicri:level="1"><nlm:aff id="aff3">Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nachbagauer, Raffael" sort="Nachbagauer, Raffael" uniqKey="Nachbagauer R" first="Raffael" last="Nachbagauer">Raffael Nachbagauer</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff5">Faculty of Life Sciences, University of Vienna, Vienna, Austria</nlm:aff>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Faculty of Life Sciences, University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Krammer, Florian" sort="Krammer, Florian" uniqKey="Krammer F" first="Florian" last="Krammer">Florian Krammer</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rose, John K" sort="Rose, John K" uniqKey="Rose J" first="John K." last="Rose">John K. Rose</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Yale University School of Medicine, New Haven, Connecticut</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Virology</title>
<idno type="ISSN">0022-538X</idno>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>ABSTRACT</title>
<p>The emergence of novel influenza viruses that cause devastating human disease is an ongoing threat and serves as an impetus for the continued development of novel approaches to influenza vaccines. Influenza vaccine development has traditionally focused on producing humoral and/or cell-mediated immunity, often against the viral surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). Here, we describe a new vaccine candidate that utilizes a replication-defective vesicular stomatitis virus (VSV) vector backbone that lacks the native G surface glycoprotein gene (VSVΔG). The expression of the H5 HA of an H5N1 highly pathogenic avian influenza virus (HPAIV), A/Vietnam/1203/04 (VN1203), and the NA of the mouse-adapted H1N1 influenza virus A/Puerto Rico/8/34 (PR8) in the VSVΔG vector restored the ability of the recombinant virus to replicate in cell culture, without the requirement for the addition of trypsin. We show here that this recombinant virus vaccine candidate was nonpathogenic in mice when given by either the intramuscular or intranasal route of immunization and that the <italic>in vivo</italic>
replication of VSVΔG-H5N1 is profoundly attenuated. This recombinant virus also provided protection against lethal H5N1 infection after a single dose. This novel approach to vaccination against HPAIVs may be widely applicable to other emerging strains of influenza virus.</p>
<p><bold>IMPORTANCE</bold>
Preparation for a potentially catastrophic influenza pandemic requires novel influenza vaccines that are safe, can be produced and administered quickly, and are effective, both soon after administration and for a long duration. We have created a new influenza vaccine that utilizes an attenuated vesicular stomatitis virus (VSV) vector, to deliver and express influenza virus proteins against which vaccinated animals develop potent antibody responses. The influenza virus hemagglutinin and neuraminidase proteins, expressed on the surface of VSV particles, allowed this vaccine to grow in cell culture and induced a potent antibody response in mice that was effective against infection with a lethal influenza virus. The mice showed no adverse reactions to the vaccine, and they were protected against an otherwise lethal influenza infection after only 14 days postvaccination and after as many as 140 days postvaccination. The ability to rapidly produce this safe and effective vaccine in cell culture is additionally advantageous.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Virol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Virol</journal-id>
<journal-id journal-id-type="hwp">jvi</journal-id>
<journal-id journal-id-type="pmc">jvi</journal-id>
<journal-id journal-id-type="publisher-id">JVI</journal-id>
<journal-title-group><journal-title>Journal of Virology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-538X</issn>
<issn pub-type="epub">1098-5514</issn>
<publisher><publisher-name>American Society for Microbiology</publisher-name>
<publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">25540378</article-id>
<article-id pub-id-type="pmc">4325733</article-id>
<article-id pub-id-type="publisher-id">03246-14</article-id>
<article-id pub-id-type="doi">10.1128/JVI.03246-14</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Vaccines and Antiviral Agents</subject>
</subj-group>
</article-categories>
<title-group><article-title>A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine</article-title>
<alt-title alt-title-type="running-head">Replicating VSV-Vectored Influenza Vaccine</alt-title>
<alt-title alt-title-type="short-authors">Ryder et al.</alt-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Ryder</surname>
<given-names>Alex B.</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2"><sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Buonocore</surname>
<given-names>Linda</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Vogel</surname>
<given-names>Leatrice</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Nachbagauer</surname>
<given-names>Raffael</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>d</sup>
</xref>
<xref ref-type="aff" rid="aff5"><sup>e</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Krammer</surname>
<given-names>Florian</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Rose</surname>
<given-names>John K.</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<aff id="aff1"><label>a</label>
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
<aff id="aff2"><label>b</label>
Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
<aff id="aff3"><label>c</label>
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA</aff>
<aff id="aff4"><label>d</label>
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA</aff>
<aff id="aff5"><label>e</label>
Faculty of Life Sciences, University of Vienna, Vienna, Austria</aff>
</contrib-group>
<contrib-group><contrib contrib-type="editor"><name><surname>Lyles</surname>
<given-names>D. S.</given-names>
</name>
<role>Editor</role>
</contrib>
</contrib-group>
<author-notes><corresp id="cor1">Address correspondence to John K. Rose, <email>john.rose@yale.edu</email>
.</corresp>
<fn fn-type="other"><p><bold>Citation</bold>
Ryder AB, Buonocore L, Vogel L, Nachbagauer R, Krammer F, Rose JK. 2015. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. J Virol 89:2820–2830. doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.03246-14">10.1128/JVI.03246-14</ext-link>
.</p>
</fn>
</author-notes>
<pub-date pub-type="epub"><day>24</day>
<month>12</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="collection"><day>1</day>
<month>3</month>
<year>2015</year>
</pub-date>
<volume>89</volume>
<issue>5</issue>
<fpage>2820</fpage>
<lpage>2830</lpage>
<history><date date-type="received"><day>7</day>
<month>11</month>
<year>2014</year>
</date>
<date date-type="accepted"><day>16</day>
<month>12</month>
<year>2014</year>
</date>
</history>
<permissions><copyright-statement>Copyright © 2015, American Society for Microbiology. All Rights Reserved.</copyright-statement>
<copyright-year>2015</copyright-year>
<copyright-holder>American Society for Microbiology</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="zjv00515002820.pdf"></self-uri>
<abstract><title>ABSTRACT</title>
<p>The emergence of novel influenza viruses that cause devastating human disease is an ongoing threat and serves as an impetus for the continued development of novel approaches to influenza vaccines. Influenza vaccine development has traditionally focused on producing humoral and/or cell-mediated immunity, often against the viral surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). Here, we describe a new vaccine candidate that utilizes a replication-defective vesicular stomatitis virus (VSV) vector backbone that lacks the native G surface glycoprotein gene (VSVΔG). The expression of the H5 HA of an H5N1 highly pathogenic avian influenza virus (HPAIV), A/Vietnam/1203/04 (VN1203), and the NA of the mouse-adapted H1N1 influenza virus A/Puerto Rico/8/34 (PR8) in the VSVΔG vector restored the ability of the recombinant virus to replicate in cell culture, without the requirement for the addition of trypsin. We show here that this recombinant virus vaccine candidate was nonpathogenic in mice when given by either the intramuscular or intranasal route of immunization and that the <italic>in vivo</italic>
replication of VSVΔG-H5N1 is profoundly attenuated. This recombinant virus also provided protection against lethal H5N1 infection after a single dose. This novel approach to vaccination against HPAIVs may be widely applicable to other emerging strains of influenza virus.</p>
<p><bold>IMPORTANCE</bold>
Preparation for a potentially catastrophic influenza pandemic requires novel influenza vaccines that are safe, can be produced and administered quickly, and are effective, both soon after administration and for a long duration. We have created a new influenza vaccine that utilizes an attenuated vesicular stomatitis virus (VSV) vector, to deliver and express influenza virus proteins against which vaccinated animals develop potent antibody responses. The influenza virus hemagglutinin and neuraminidase proteins, expressed on the surface of VSV particles, allowed this vaccine to grow in cell culture and induced a potent antibody response in mice that was effective against infection with a lethal influenza virus. The mice showed no adverse reactions to the vaccine, and they were protected against an otherwise lethal influenza infection after only 14 days postvaccination and after as many as 140 days postvaccination. The ability to rapidly produce this safe and effective vaccine in cell culture is additionally advantageous.</p>
</abstract>
<counts><fig-count count="6"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="67"></ref-count>
<page-count count="11"></page-count>
<word-count count="9046"></word-count>
</counts>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000747 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000747 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:4325733 |texte= A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:25540378" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |